Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: Secondary analysis of a randomized clinical trial
JAMA May 21, 2019
Pan Y, et al. - In this prespecified secondary analysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) randomized clinical trial, researchers studied the connection between ABCB1 polymorphisms and clopidogrel effectiveness for minor stroke or transient ischemic attack (TIA). The trial included 2,836 adults. According to findings, ABCB1 polymorphism was linked to the reduced effectiveness of clopidogrel plus aspirin therapy in patients with minor ischemic stroke or TIA vs aspirin. Considering the genetic polymorphism of ABCB1 was recommended when prescribing clopidogrel for these patients.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries